Potential Therapeutic Targets for Treatment of CKD
- Preclin
- IND
- Ph 1
- Ph 2
- Ph 3
- Approv
- Preclinical
- IND
- Phase 1
- Phase 2
- Phase 3
- Approval
REACT®/DKD
Diabetes Type II – Prevent/Delay CKD 3/4
(20-50 ml/min/1.73m2, N=81)
Fully Enrolled
Diabetes Type II – Prevent/Delay CKD 3/4
(20-50 ml/min/1.73m2, N=1,200)
Enrolling in US
Diabetes Type II –
Delay CKD 4/5
(14-20 ml/min/1.73m2, N=10)
Fully Enrolled
Diabetes Repeat Dose Prevent/Delay CKD 3/4†
(20-50 ml/min/1.73m2, N=50‡)
Enrolling
- Preclin
- IND
- Ph 1
- Ph 2
- Ph 3
- Approv
- Preclinical
- IND
- Phase 1
- Phase 2
- Phase 3
- Approval
REACT®/CAKUT
Congenital Anomalies – Prevent/Delay N=15
Enrolling
Footnotes:
† injecting both kidneys w/ redose trigger
‡ Increased from 30 as indicated in Proxy Amendment No. 1, page 289